Inhaled corticosteroids (ICS) form the basis of maintenance therapy in subjects with asthma in whom they target the airway inflammatory and process, effectively reducing mortality and morbidity from asthma. While the efficacy of ICS in asthma is well established, dosing remains problematic. For some outcomes the dose-efficacy curve is relatively flat and more than 90% of the benefit is achieved at low doses of ICS (for example, fluticasone propionate 250 μg/day). However, in clinical practice, very high doses of ICS are frequently prescribed and there are now reports of significant side effects including acute adrenal crises with high dose ICS. In addition, undertreatment of asthma could result when inadequate doses of ICS are used.

Asthma guidelines recommend that maintenance ICS be given at the lowest effective dose according to the severity of the condition. However, the optimal starting dose of ICS in asthma has not been established. This is an important issue since there is concern that patients started on an initial high dose of ICS may continue to receive this dose in the long term and therefore be exposed to unnecessarily high ICS doses. Asthma guidelines vary in their recommendations for starting ICS. The GINA guidelines recommend a wide range of starting doses ranging from 200 to 1000 μg beclomethasone equivalent per day,10 the Australian guidelines recommend starting with a high dose of ICS and then reducing the dose (step down),11 while the British Thoracic Society/Scottish Intercollegiate Guideline Network (BTS/SIGN) guidelines and the New Zealand guidelines recommend starting with moderate to low doses of ICS.12

The aim of this systematic review and meta-analysis was to establish the optimal starting dose of ICS for adults with asthma. Fourteen publications describing 13 trials were included in the review. Studies were randomised controlled trials comparing two doses of the same ICS in adults with asthma and no concomitant inhaled or oral corticosteroid were assessed. Included trials were analysed according to the following ICS dose comparisons: high (>800 μg/day beclomethasone (BDP)) versus moderate (400–800 μg/day BDP) (n = 7); moderate versus low (<400 μg/day BDP) (n = 6); step down versus constant dose (n = 4).

RESULTS: Fourteen publications describing 13 trials were included in the review. Studies (n = 4) that compared a step down approach with a constant moderate/low dose of ICS found no difference in lung function, symptoms, or rescue medications between the two treatment approaches (p > 0.05). There was no difference in the change in morning peak flow after treatment with high compared with moderate dose ICS. When compared with low dose ICS, moderate dose ICS significantly improved morning peak flow (change from baseline WMD 11.14 l/min, 95% CI 1.34 to 20.93) and nocturnal symptoms (SMD −0.29, 95% CI −0.53 to −0.06).

Conclusions: For patients with asthma who require ICS, starting with a moderate dose is equivalent to starting with a high dose and stepping down. The small non-significant benefits of starting with a high ICS dose are not of sufficient clinical benefit to warrant its use. Initial moderate ICS doses appear to be more effective than an initial low ICS dose.
randomisation and concealment of allocation. Authors were contacted to verify and provide further information about methodological approaches and outcomes data.

**Analysis of data**

The relative risk (RR) with 95% confidence intervals was calculated for dichotomous outcomes. For continuous outcomes using different units of measure, a standardised mean difference (SMD) and 95% confidence interval was calculated using a fixed effects model. For continuous outcomes using the same unit of measure, the weighted mean difference (WMD) was calculated. Significance was accepted at p < 0.05. The pooled results were tested for heterogeneity using a χ² test with appropriate degrees of freedom. Outcomes were analysed according to delivery device, duration of treatment, and ICS type.

Primary comparisons were made and determined by the strength of the ICS dose and the type of intervention, step down or constant dose being compared. ICS dose and dose equivalence were classified according to the BTS guidelines as (a) high dose (>800 μg/day budesonide (BDP) equivalent); (b) moderate dose (400–800 μg/day BDP); (c) low dose (<400 μg/day BDP) and dose equivalence for BDP:budesonide as 1:1 ratio and BDP:fluticasone as 2:1 ratio. The use of dry powder inhalers or metered dose inhalers with or without a spacer for delivery of ICS was considered clinically equivalent.1

**RESULTS**

**Included studies**

Fourteen publications describing 13 parallel group randomised controlled trials met the inclusion criteria for the review (table 1).16–29 Budesonide (BUD) doses were compared in nine studies, fluticasone (FP) in three, and BDP in one. Seven studies compared high dose ICS with moderate dose ICS (n = 1579), six compared moderate dose ICS with low dose ICS (n = 1140), and four studies compared a step down dose with a constant ICS dose regimen (starting with a high dose and back titrating to either a moderate or low dose (n = 1197)). Two studies had three dosage arms of high, moderate and low dose with a constant ICS dose regimen (starting with a high dose ICS (n = 1140), and four studies compared a step down ICS (n = 1579), six compared moderate dose ICS with low dose ICS (n = 1197), and nine studies, fluticasone (FP) in three, and BDP in one.

**METHODS**

The pooled results were tested for heterogeneity using a weighted mean difference (WMD) was calculated. Significance was accepted at p < 0.05. The pooled results were tested for heterogeneity using a χ² test with appropriate degrees of freedom. Outcomes were analysed according to delivery device, duration of treatment, and ICS type.

Primary comparisons were made and determined by the strength of the ICS dose and the type of intervention, step down or constant dose being compared. ICS dose and dose equivalence were classified according to the BTS guidelines as (a) high dose (>800 μg/day budesonide (BDP) equivalent); (b) moderate dose (400–800 μg/day BDP); (c) low dose (<400 μg/day BDP) and dose equivalence for BDP:budesonide as 1:1 ratio and BDP:fluticasone as 2:1 ratio. The use of dry powder inhalers or metered dose inhalers with or without a spacer for delivery of ICS was considered clinically equivalent.1

**Participants**

Asthma was most frequently diagnosed by doctor’s diagnosis, objective lung function, or American Thoracic Society criteria. Six studies included mild to moderate asthmatics, mild asthma was represented in two studies, moderate asthma in two studies, and two studies included participants with moderate to severe asthma.27 29 In one study the level of asthma severity was unable to be determined. The characteristics of the participants are shown in table 2.

**High versus moderate dose ICS**

A meta-analysis of the change in morning peak flow (PEF, l/min) from baseline found a non-significant improvement in favour of high dose ICS (WMD 5.72; 95% CI −1.56 to 13.00; fig 1). The 95% confidence intervals of the effect size excluded a clinically important change in PEF. One additional study25 found no treatment effect. Asthma symptoms were reduced in two studies with no significant difference between the treatment groups.24 29 One study only reported significant dose response relationships for symptom scores but not in a form that could be used for meta-analysis.21 22 There was no significant difference between high or moderate dose ICS for the change in daytime or night time symptom scores when the results of two studies (reporting symptom scores on the same 0–3 scale) were pooled in a meta-analysis (table 3). There was no significant difference

<table>
<thead>
<tr>
<th>Study</th>
<th>Quality*</th>
<th>Design</th>
<th>No enrolled/ no completed</th>
<th>ICS type</th>
<th>Dose (μg/day)</th>
<th>Duration (weeks)</th>
<th>Delivery device</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campbell14</td>
<td>4B</td>
<td>Parallel</td>
<td>682/454</td>
<td>BUD</td>
<td>800–400 v 400</td>
<td>24</td>
<td>DPI</td>
<td>Step down v constant/high v moderate</td>
</tr>
<tr>
<td>Chanez21</td>
<td>4A</td>
<td>Parallel</td>
<td>169/137</td>
<td>BUD</td>
<td>1600–200 v 400</td>
<td>16</td>
<td>DPI</td>
<td>Step down v constant/high v moderate</td>
</tr>
<tr>
<td>Jatakanon18</td>
<td>3B</td>
<td>Parallel</td>
<td>22/21</td>
<td>BUD</td>
<td>400 v 100</td>
<td>4</td>
<td>DPI</td>
<td>Moderate v low</td>
</tr>
<tr>
<td>Lorentzson19</td>
<td>3B</td>
<td>Parallel</td>
<td>104/103</td>
<td>BUD</td>
<td>400 v 200</td>
<td>6</td>
<td>pMDI</td>
<td>Moderate v low</td>
</tr>
<tr>
<td>Majima20</td>
<td>1A</td>
<td>Parallel</td>
<td>17/NS</td>
<td>BDP</td>
<td>800 v 400</td>
<td>8</td>
<td>NS</td>
<td>High v moderate</td>
</tr>
<tr>
<td>Miymamoto21 22</td>
<td>5A</td>
<td>Parallel</td>
<td>267/224</td>
<td>BUD</td>
<td>800 v 400 v 200</td>
<td>6</td>
<td>DPI</td>
<td>High v moderate/high v low</td>
</tr>
<tr>
<td>Noonan23</td>
<td>3B</td>
<td>Parallel</td>
<td>138/119</td>
<td>FP</td>
<td>200 v 100</td>
<td>8</td>
<td>pMDI</td>
<td>Moderate v low</td>
</tr>
<tr>
<td>O’Byrne24</td>
<td>4A</td>
<td>Parallel</td>
<td>57/39</td>
<td>BUD</td>
<td>800 v 400</td>
<td>16</td>
<td>pMDI</td>
<td>Moderate v low</td>
</tr>
<tr>
<td>Pedersen25</td>
<td>2B</td>
<td>Parallel</td>
<td>85/53</td>
<td>BDP</td>
<td>1600 v 400</td>
<td>36</td>
<td>NS</td>
<td>High v moderate</td>
</tr>
<tr>
<td>Pirozynski25</td>
<td>3B</td>
<td>Parallel</td>
<td>262/NS</td>
<td>BDP</td>
<td>800–200 v 200</td>
<td>12</td>
<td>DPI</td>
<td>Step down v constant</td>
</tr>
<tr>
<td>Shiffer27</td>
<td>3B</td>
<td>Parallel</td>
<td>307/294</td>
<td>FP</td>
<td>200 v 100</td>
<td>12</td>
<td>pMDI</td>
<td>Moderate v low</td>
</tr>
<tr>
<td>van der Molen28</td>
<td>3B</td>
<td>Parallel</td>
<td>84/73</td>
<td>BDP</td>
<td>800–200 v 200</td>
<td>12</td>
<td>DPI</td>
<td>Step down v constant</td>
</tr>
<tr>
<td>Wasserman29</td>
<td>3B</td>
<td>Parallel</td>
<td>331/256</td>
<td>FP</td>
<td>500 v 200 v 100</td>
<td>12</td>
<td>DPI</td>
<td>High v moderate/high v low</td>
</tr>
</tbody>
</table>

*Numbers are Jadad scores from 0 to 5 where higher numbers indicate less opportunity for bias. Letters indicate whether the method of allocation to treatment groups was A = adequate; B = unclear; C = inadequate. NS, not stated; BUD, budesonide; FP, fluticasone propionate; BDP, beclomethasone; DPI, dry powder inhaler; pMDI, pressurised metered dose inhaler.
between ICS doses in rescue medication during the day or night (table 3).

**Moderate versus low dose ICS**

There was a significant improvement in morning PEF from baseline in favour of the moderate dose ICS group (WMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1). There was a significant improvement in morning PEF from baseline in favour of the moderate dose ICS group (WMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1). Night time symptom score and mean number of wakenings also reached significance favouring a moderate dose ICS (SMD 11.14; 95% CI 1.34 to 20.93; fig 1).

**Withdrawal due to adverse events**

Withdrawal due to adverse events was reported in two studies comparing high and moderate dose ICS,\(^2\)\(^3\)\(^4\)\(^5\) and two studies comparing a step down dose with constant dose ICS.\(^6\)\(^7\) There was no significant difference between treatment groups in the proportion of participants withdrawing due to an adverse event in the pooled results for each comparison.

**Subgroup analysis**

Further analyses by delivery device, duration of treatment, and ICS type found no significant effect for all outcomes (data not shown).\(^8\) However, these analyses may have been limited by the small size and number of studies.

**DISCUSSION**

This systematic review examined the results of 13 randomised controlled trials comparing initial ICS doses in asthma. The search was extensive and included all known published data. The meta-analysis supports the BTS/SIGN recommendation of using low to moderate doses of ICS as initial treatment for adults with asthma. We also evaluated the effects of starting ICS at a high dose (with or without a subsequent step down) compared with starting with a moderate or low dose ICS, and found no benefit of the step down approach when used as initial treatment. ICS step down (back titration) has an important place in determining maintenance ICS doses in asthma, however.

---

**Table 2 Summary of characteristics of participants in included studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Age (mean (SD) or range)</th>
<th>Asthma diagnosis</th>
<th>Severity</th>
<th>Previous ICS use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campbell et al.</td>
<td>33.5 (13.8)/33.3 (15.6)</td>
<td>Documented diagnosis asthma</td>
<td>Excluded if &lt;60% predicted PEF</td>
<td>No ICS</td>
</tr>
<tr>
<td>Chanez et al.</td>
<td>38 (18-70 eligible range)</td>
<td>PEF diurnal variation &gt;20%, &gt;12% FEV(_1) reversibility</td>
<td>Mean FEV(_1) 74% predicted, uncontrolled at enrolment</td>
<td>No current ICS use</td>
</tr>
<tr>
<td>Jatakanon et al.</td>
<td>29 (2.4)/31 (1.2)</td>
<td>Doctor diagnosis, objective lung function (PC20 methacholine)</td>
<td>FEV(_1) &gt;80% predicted. Mean FEV(_1), 91.5%/92.4% predicted</td>
<td>Previous ICS use</td>
</tr>
<tr>
<td>Lorentzon et al.</td>
<td>32</td>
<td>Clinical asthma</td>
<td>Mean FEV 75% predicted</td>
<td>ICS naive</td>
</tr>
<tr>
<td>Majima et al.</td>
<td>45.3/43.3</td>
<td>Objective lung function according to Japanese Allergy Association</td>
<td>Stated mild to moderate asthma</td>
<td>No ICS</td>
</tr>
<tr>
<td>Miyamoto et al.</td>
<td>50.4 (15)/47.8 (15.9)/</td>
<td>NS</td>
<td>Mild 62%; moderate 37%; severe 1%</td>
<td>No ICS &gt; 1 month before study</td>
</tr>
<tr>
<td>Noonan et al.</td>
<td>29 (12-59)</td>
<td>ATS criteria</td>
<td>Mean FEV(_1) 73%/76% predicted</td>
<td>No recent ICS</td>
</tr>
<tr>
<td>O’Byrne et al.</td>
<td>37/32</td>
<td>Objective lung function</td>
<td>Stated mild asthma</td>
<td>No ICS</td>
</tr>
<tr>
<td>Pedersen et al.</td>
<td>46.1 (11.2)/46.8 (12.5)</td>
<td>ATS criteria</td>
<td>Mean (SD) FEV(_1), 70.7 (14.2)/78.8 (19.8) predicted</td>
<td>No ICS</td>
</tr>
<tr>
<td>Pirozynski et al.</td>
<td>36</td>
<td>NS</td>
<td>Mean FEV(_1) 82.3% predicted</td>
<td>No ICS</td>
</tr>
<tr>
<td>Sheffer et al.</td>
<td>28 (12-72)/30 (12-63)</td>
<td>Objective lung function</td>
<td>Inclusion criteria FEV(_1), 45-75% predicted</td>
<td>No ICS</td>
</tr>
<tr>
<td>van der Molen et al.</td>
<td>31.3 (10.8)/32 (8.1)</td>
<td>Objective lung function (defined by Dutch College for General Practitioners)</td>
<td>Not stated but inclusion criteria FEV(_1) &gt;50% predicted</td>
<td>No ICS in past 2 months</td>
</tr>
<tr>
<td>Wasserman et al.</td>
<td>29/27/29</td>
<td>ATS criteria</td>
<td>Inclusion criteria FEV(_1), 50-80% predicted</td>
<td>No ICS in past month</td>
</tr>
</tbody>
</table>

NS, not stated; ICS, inhaled corticosteroid; FEV\(_1\), forced expiratory volume in 1 second; PEF, peak expiratory flow.

---

**Step down versus constant dose ICS**

There was no significant difference between a step down ICS dose and constant dose ICS in the change in morning PEF (l/min) from baseline in adults (WMD 0.83, 95% CI –8.6 to 10.26; fig 1). Overall, there was no significant difference in symptoms between the two treatment approaches. Symptoms improved with no significant difference between the groups in one study\(^8\) and there was no significant difference between treatment groups when the results for night time symptom score were pooled in a meta-analysis (table 3). Two trials reported a reduction in \(\beta\) agonist use for both treatment groups\(^8\)\(^9\) with no difference between the two groups (table 3).

---

**Figure 1** Effect of initial asthma treatment with high versus moderate dose ICS, moderate versus low dose ICS, and step down versus constant dose ICS on the change in morning peak expiratory flow from baseline. Weighted mean difference (WMD) for individual trials. \(\chi^2\) refers to test for heterogeneity across different trials. \(Z\) is the test statistic for weighted mean difference. WMD for individual trials is represented by squares and for total for each comparison (diamond = WMD 95% CI). Results are reported as l/min.
In view of the differing guideline recommendations and the frequent prescription of high dose ICS with subsequent significant side effects, it is important to establish the optimal starting dose for ICS in asthma. It has previously been established that low to moderate ICS doses are highly effective as maintenance treatment for asthma. We have extended these observations to examine the efficacy of differing ICS doses as initial treatment. In most of the studies included in this review the efficacy was shown in both treatment arms for the majority of outcomes and there was no clear benefit for starting at a high ICS dose. A review of the seven studies that compared a constant high dose ICS with a moderate dose ICS showed that there was a non-significant improvement in the change in morning PEF from baseline. The upper 95% confidence interval of the effect size was 13 l/min, which is less than a clinically significant change in PEF. This suggests that, although there was a trend for a benefit of high dose ICS, it is unlikely to be clinically significant even with further studies. No differences were found between commencing with high or moderate dose ICS for asthma symptoms or rescue medication use. The small non-significant benefit in lung function needs to be considered against the risks of increased side effects with the use of constant high dose ICS. One particular concern is that, unless patients attend for regular medication review, the initial dose prescribed becomes the long term maintenance dose. This could explain the ongoing use of very high ICS doses, even though most guidelines recommend back titration. Starting treatment with a moderate dose should minimise this problem.

For moderate dose ICS there was a significant improvement in the change in morning PEF from baseline and nocturnal symptoms in comparison with low dose ICS. There were also non-significant improvements in the reduction of rescue medication use from baseline, suggesting a superior effect for moderate dose ICS.

The practice of starting with high dose ICS to gain control of asthma and then stepping down to a moderate or low maintenance dose is recommended in some asthma management guidelines. When we reviewed the four studies that compared this practice with a constant moderate or low ICS dose, we found no significant benefit in the effect on lung function, symptoms, or rescue medications. These results suggest that constant ICS doses have similar clinical efficacy to the more complex regimen of high ICS doses followed by a step down. One reason for considering initial high dose therapy is to obtain rapid symptom control. It is likely that this can be achieved by the use of ICS in combination with a long acting β₂ agonist (LABA). A comparison of initial asthma treatment with ICS versus a combination of ICS and LABA is the subject of a current systematic review.

This review was limited to the major outcomes including lung function and symptoms that were reported in the included studies. The analyses were also restricted to small numbers of studies of differing duration. However, there was a consistency in the reported results for the main outcomes across the studies. Analysis of inflammatory markers and exacerbations was not possible due to the lack of reporting of these outcomes. An analysis of airway hyperresponsiveness tended to support a benefit from higher ICS doses, but data were insufficient to permit meta-analysis. Future research could establish whether this is a true effect and whether it relates to control of inflammation or other aspects of airway pathology in asthma (such as remodelling).

In conclusion, the results of this review support initiating asthma treatment for mild to moderate asthmatics with low to moderate doses of ICS at a constant dose. The small non-significant benefits of commencing with a high dose of ICS are not of sufficient clinical benefit to warrant routine use when compared with moderate or low dose ICS. An initial moderate ICS dose appears to be more effective than an initial low ICS dose. Starting ICS at a constant moderate or low dose is equally efficacious to starting at a high dose and then stepping down.

ACKNOWLEDGEMENTS

The authors thank Toby Lasserson, Karen Blackhall, Jo Picot and Chris Cates from the Cochrane Airways Review Group for their assistance with this review and Dr B Volovitz, Dr W B Hofstra, Dr M J Visser and Dr O Selroos for Dr Miyamoto for providing information regarding their studies.

Authors’ affiliations

H Powell, Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, Newcastle, NSW 2310, and Cooperative Research Centre for Asthma, Camperdown, NSW 2050, Australia

P G Gibson, Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, Newcastle, NSW 2310, Australia

Financial support was provided by the Cooperative Research Centre for Asthma.

REFERENCES


LUNG ALERT

Air pollution hampers teenagers’ lung development


The Children’s Health Study recruited 1759 children from schools in Southern California and prospectively followed up these children from the age of 10 to 18 years, measuring lung function annually. FVC, FEV₁, and maximal mid expiratory flow rate (MMEF) were used as markers of lung development. Air pollution monitoring stations were established in target areas that recorded pollution data continuously over the 8 years. Linear regression models were used to adjust for confounding variables and to determine the effects.

The results showed a strong association between decreased lung function (FEV₁) attained at the age of 18 years and pollutants like nitrogen dioxide (p = 0.005), acid vapour (p = 0.01), fine particulate matter PM₂·₅ (p = 0.002), and elemental carbon (p = 0.006). The effect of these pollutants was similar in both sexes and remained significant in children with no history of asthma or exposure to smoking. The authors noted that reduced lung function was a risk factor for complications and death during adulthood and later in life.

The study did not provide a mechanism for air pollutant effect, although the authors have suggested airway inflammation. It is also interesting and somewhat in contrast with the previous studies that this study has not implicated ozone in having any health effect on lung development. However, the authors point out the need for caution in interpreting this particular finding.

A Khan

Specialist Registrar in Respiratory Medicine, Derbyllford Hospital, Plymouth, UK; ayzkhan@aol.com
Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review

H Powell and P G Gibson

Thorax 2004 59: 1041-1045
doi: 10.1136/thx.2004.023754

Updated information and services can be found at:
http://thorax.bmj.com/content/59/12/1041

These include:

References
This article cites 20 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/59/12/1041#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Drugs: respiratory system (526)
- Clinical trials (epidemiology) (557)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/